0 votes
21 views
ago in General Health by (570 points)
Is TALVEY a bispecific?

1 Answer

0 votes
ago by (1.1k points)
Yes, TALVEY is a bispecific.

The drug TALVEY is a bispecific antibody that is also known as (talquetamab-tgvs) and is a first in class, T-cell-redirecting bispecific antibody that is also approved by the FDA for the treatment of adults that have heavily pretreated, relapsed or refractory multiple myeloma (a type of blood cancer).

The way that TALVEY works is unlike, traditional monoclonal antibodies, which only target one site, a bispecific antibody like TALVEY, has two distinct "arms" that also bind to tow different proteins simultaneously.

And one arm binds to GPRC5D (which is a protein found in high numbers on the surface of multiple myeloma cells).

And the other arm binds to CD3 (a protein located on the surface of your immune system's T cells).

TALVEY activates your immune system to attack and destroy the cancer cells, by bridging the T cell and myeloma cell together.

Talvey (talquetamab-tgvs) is an immunotherapy, not traditional chemotherapy.

Specifically, Talvey is a bispecific T-cell engager (BiTE) and a type of monoclonal antibody.

It acts like a bridge by attaching to two different proteins at the same time—GPRC5D on multiple myeloma cancer cells and CD3 on your body's immune T-cells.

By bringing them together, Talvey activates your T-cells to find, target, and destroy the cancer cells.

How it differs from chemotherapy: Traditional chemotherapy generally attacks and destroys any fast-growing cells in the body (both cancerous and healthy).

Talvey instead directs your own immune system to specifically recognize and fight the myeloma cells.

2.5k questions

2.5k answers

22 comments

141 users

VekDrive.com Cloud Storage and File Sharing.

Get 5 GB Free Cloud Storage when you signup for a free account.

Or get 50 GB of Cloud Storage for $3.00 per month.

VekDrive Cloud Storage

...